Sophie Lebel1,2, Sebastien Simard3, Cheryl Harris4, Andrea Feldstain5, Sara Beattie5, Megan McCallum5, Monique Lefebvre6, Josée Savard3, Gerald M Devins7. 1. School of Psychology, Ottawa University, 136 Jean Jacques Lussier, Room 4016, Ottawa, ON, K1N6N5, Canada. slebel@uottawa.ca. 2. Montfort Hospital Research Institute, Ottawa, Canada. slebel@uottawa.ca. 3. Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Quebec City, Canada. 4. The Ottawa Hospital Cancer Center, Ottawa, Canada. 5. School of Psychology, Ottawa University, 136 Jean Jacques Lussier, Room 4016, Ottawa, ON, K1N6N5, Canada. 6. The Ottawa Hospital, Ottawa, Canada. 7. Princess Margaret Hospital, Ontario Cancer Institute, University of Toronto, Toronto, Canada.
Abstract
PURPOSE: Cancer patients report that help in managing fear of cancer recurrence (FCR) is one of their greatest unmet needs. Research on FCR has been limited by the very few validated, multi-dimensional measures of this construct. One exception is the Fear of Cancer Recurrence Inventory (FCRI), originally developed and empirically validated in French. The present study validated the English version of the FCRI. METHODS: The FCRI was translated into English using a forward-backward translation procedure and pilot-tested with 17 English-speaking cancer patients. Cross-cultural equivalency of the French and English versions was established by administering both forms to 42 bilingual cancer patients. Last, 350 English-speaking breast, colon, prostate, or lung cancer patients were asked to complete the FCRI. A subsample (n = 135) was mailed the FCRI again one month later to evaluate test-retest reliability. RESULTS: The English translation of the FCRI was well accepted by participants. There was no item-bias when comparing bilingual participants' answers on both versions. A confirmatory factor analysis supported the hypothesized seven-factor structure. The English version has high internal consistency (α = .96 for the total scale and .71-.94 for the subscales) and test-retest reliability (r = .88 for the total scale and 56-.87 for the subscales). CONCLUSIONS: The English version of the FCRI is a reliable and valid measure of FCR applicable to breast, colon, prostate, and lung cancer patients. Its multi-dimensional nature makes it an attractive research and clinical tool to further our knowledge of FCR.
PURPOSE:Cancerpatients report that help in managing fear of cancer recurrence (FCR) is one of their greatest unmet needs. Research on FCR has been limited by the very few validated, multi-dimensional measures of this construct. One exception is the Fear of Cancer Recurrence Inventory (FCRI), originally developed and empirically validated in French. The present study validated the English version of the FCRI. METHODS: The FCRI was translated into English using a forward-backward translation procedure and pilot-tested with 17 English-speaking cancerpatients. Cross-cultural equivalency of the French and English versions was established by administering both forms to 42 bilingual cancerpatients. Last, 350 English-speaking breast, colon, prostate, or lung cancerpatients were asked to complete the FCRI. A subsample (n = 135) was mailed the FCRI again one month later to evaluate test-retest reliability. RESULTS: The English translation of the FCRI was well accepted by participants. There was no item-bias when comparing bilingual participants' answers on both versions. A confirmatory factor analysis supported the hypothesized seven-factor structure. The English version has high internal consistency (α = .96 for the total scale and .71-.94 for the subscales) and test-retest reliability (r = .88 for the total scale and 56-.87 for the subscales). CONCLUSIONS: The English version of the FCRI is a reliable and valid measure of FCR applicable to breast, colon, prostate, and lung cancerpatients. Its multi-dimensional nature makes it an attractive research and clinical tool to further our knowledge of FCR.
Entities:
Keywords:
Cancer; Fear of cancer recurrence; Instrument; Questionnaire; Survivorship; Validation
Authors: Neil Aaronson; Jordi Alonso; Audrey Burnam; Kathleen N Lohr; Donald L Patrick; Edward Perrin; Ruth E Stein Journal: Qual Life Res Date: 2002-05 Impact factor: 4.147
Authors: N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes Journal: J Natl Cancer Inst Date: 1993-03-03 Impact factor: 13.506
Authors: Andrea L Canada; Patricia E Murphy; Kevin Stein; Kassandra I Alcaraz; Corinne R Leach; George Fitchett Journal: J Cancer Surviv Date: 2022-06-20 Impact factor: 4.442
Authors: Justin C Brown; Nevena Damjanov; Kerry S Courneya; Andrea B Troxel; Babette S Zemel; Michael R Rickels; Bonnie Ky; Andrew D Rhim; Anil K Rustgi; Kathryn H Schmitz Journal: Psychooncology Date: 2018-02-20 Impact factor: 3.894
Authors: Jake R Thompson; Andrea L Smith; Serigne N Lo; Nadine A Kasparian; Robyn Pm Saw; Mbathio Dieng; Linda Seaman; Linda K Martin; Pascale Guitera; Donna Milne; Helen Schmid; Anne E Cust; Iris Bartula Journal: BMJ Open Date: 2022-03-03 Impact factor: 2.692
Authors: Jinyoung Shin; Aejin Goo; Hyeonyoung Ko; Ji Hae Kim; Seung U Lim; Han Kyeong Lee; Sébastien Simard; Yun Mi Song Journal: J Korean Med Sci Date: 2017-11 Impact factor: 2.153